436. Deputy Mark Ward asked the Minister for Health will consider running a pilot orphan drug early-access programme in order that children with Duchenne muscular dystrophy can access givinostat; if a pricing and reimbursement application has been received by the HSE for givinostat; and if she will make a statement on the matter. [23049/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
437. Deputy Mark Ward asked the Minister for Health if givinostat will be made available for children with Duchenne muscular dystrophy; and if she will make a statement on the matter. [23050/26]
889. Deputy Michael Collins asked the Minister for Health if she will intervene to ensure the HSE prioritises a conclusion to the reimbursement negotiations for skyclarys, given it is the only available treatment for Friedreich’s ataxia and the unmet clinical need recognised in the national rare disease strategy 2025–2030; and if she will make a statement on the matter. [21668/26]
890. Deputy Michael Collins asked the Minister for Health her views on whether current delays in providing skyclarys are compatible with the commitment to “equitable access” outlined in the new National Rare Disease Strategy, particularly when patients across Europe already have access to this therapy; and if she will make a statement on the matter. [21669/26]
931. Deputy Paul Murphy asked the Minister for Health the specific steps being taken to ensure the HSE considers the time-critical nature of Friedreich’s ataxia during the current price negotiations for skyclarys; and the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to this specific cas…
970. Deputy Jennifer Whitmore asked the Minister for Health whether she will consider funding the medication skyclarys for people living with Friedreich’s ataxia; and if she will make a statement on the matter. [22147/26]
992. Deputy Joe Cooney asked the Minister for Health further to Parliamentary Question No. 945 of 3 March 2026, for an indicative timeline for when a decision on a case (details supplied) is expected; confirmation of what stage of the review process the application is currently at; whether any interim supports or exceptional access arrangements may be available for patients currently prescribed this treatment; and if…
994. Deputy Conor D. McGuinness asked the Minister for Health if holders of a long-term illness card are entitled to receive blister packs (medication compliance aids) free of charge where they are clinically required; if this entitlement is provided for under the long-term illness scheme or other community drug schemes; the guidance that has been issued by the HSE to pharmacies in this regard; and if she will make a…
997. Deputy Marie Sherlock asked the Minister for Health when the HSE will make a decision on the reimbursement of a medication (details supplied); and if she will make a statement on the matter. [22282/26]
1032. Deputy Naoise Ó Muirí asked the Minister for Health if she will intervene to ensure that the HSE prioritises the conclusion of reimbursement negotiations for skyclarys, given that it is currently the only available treatment for Friedreich’s ataxia and is identified as addressing an unmet need under the National Rare Disease Strategy 2025–2030; and if she will make a statement on the matter. [22393/26]
512. Deputy John Clendennen asked the Minister for Health for an update on the accessibility of the drug Givinostat (brand name Duvyzat) for the treatment of Duchenne muscular dystrophy, given the outcome of the NCPE assessment as of 3 March 2026; and if she will make a statement on the matter. [21310/26]
513. Deputy John Clendennen asked the Minister for Health for an update on the accessibility of Belzutifan (brand name Welireg) for the treatment of Von Hippel-Lindau syndrome; and if she will make a statement on the matter. [21311/26]
514. Deputy John Clendennen asked the Minister for Health for an update on the accessibility of Omaveloxolone (brand name Skyclarys) for the treatment of Friedreich’s ataxia; and if she will make a statement on the matter. [21312/26]
1661. Deputy Matt Carthy asked the Minister for Health whether she will review the current position to ensure that patients who are prescribed obesity medication such as Ozempic by their GPs can access it through the medical card or drug payment scheme; and if she will make a statement on the matter. [18264/26]
1680. Deputy Paul Murphy asked the Minister for Health if she will instruct her Department to review the current reimbursement scheme, making drugs such as vyloy available for reimbursement. [18372/26]
1686. Deputy Ciarán Ahern asked the Minister for Health whether an application for the inclusion of a cancer medicine (details supplied) in the HSE reimbursement scheme has been received; if she will expedite its inclusion when and if received; and if she will make a statement on the matter. [18391/26]
1713. Deputy John Brady asked the Minister for Health for an update on the application for reimbursement for the drug Skyclarys (omaveloxalone); and if she will make a statement on the matter. [18485/26]
1716. Deputy Pádraig Mac Lochlainn asked the Minister for Health the current status of the assessment, pricing negotiations and potential reimbursement approval for Skyclarys (omaveloxolone) for the treatment of Friedreich's Ataxia (FA) in Ireland; when patients can expect a decision on access to this medicine; and if she will make a statement on the matter. [18543/26]
1732. Deputy Micheál Carrigy asked the Minister for Health the steps being taken to ensure the HSE considers the "time-critical" nature of Friedreich's Ataxia during the current price negotiations for Skyclarys; the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement, which aims for a 180-day decision timeline, are being applied to this specific case, to …
1743. Deputy Rose Conway-Walsh asked the Minister for Health when she expects an outcome from the application for pricing and reimbursement of omaveloxolone (Skyclarys) for the treatment of Friedreich’s Ataxia in adults and adolescents aged 16 years and older; if not yet known, the efforts that will be made in the interim to support those diagnosed with Friedreich’s Ataxia who are waiting on the outcome of this proce…
1744. Deputy Rose Conway-Walsh asked the Minister for Health the specific steps being taken to ensure the HSE recognises the time-critical nature of Friedreich’s Ataxia during the current price negotiations for Skyclarys; how the commitments in the National Rare Disease Strategy 2025–2030 and the 2026 IPHA Framework Agreement are being applied to this case to prevent further delay for those with a Friedreich’s Ataxia…
1746. Deputy Seán Canney asked the Minister for Health when the drug Skyclarys will be reimbursed for patients with Friedreich’s Ataxia (details supplied); and if she will make a statement on the matter. [18731/26]
1750. Deputy Albert Dolan asked the Minister for Health the status of the HSE and Department of Health assessment of Omaveloxolone (Skyclarys) for the treatment of Friedreich’s Ataxia; the timeline for completing the reimbursement process; the engagement that has taken place with patient representatives and clinical experts; and if she will make a statement on the matter. [18744/26]
1751. Deputy Albert Dolan asked the Minister for Health the specific steps the HSE is taking to ensure that the time-critical nature of Friedreich’s Ataxia is fully recognised and reflected in the ongoing price negotiations for the reimbursement of Skyclarys; and if she will make a statement on the matter. [18745/26]
1752. Deputy Albert Dolan asked the Minister for Health the way in which the commitments set out in the National Rare Disease Strategy 2025–2030, particularly regarding timely access to approved therapies for rare disease patients, are being applied to the current reimbursement process for Skyclarys for the treatment of Friedreich’s Ataxia; and if she will make a statement on the matter. [18746/26]